Blinatumomab activity in a patient with Down syndrome B-precursor acute lymphoblastic leukemia

Academic Article


  • Persistent minimal residual disease (MRD) after consolidation may indicate chemotherapy insensitivity in B-precursor acute lymphoblastic leukemia (BP-ALL). Given the strong association of MRD and outcome in non-Down syndrome (non-DS) BP-ALL, it is likely that MRD levels are also of prognostic significance in DS BP-ALL. We report here the successful use of blinatumomab, a bispecific T-cell engager antibody construct, in a patient with DS BP-ALL and persistent MRD at the end of consolidation. Blinatumomab has been shown to have excellent results in patients with relapsed/refractory BP-ALL. This patient had no significant toxicity and achieved MRD negativity after only one cycle of blinatumomab.
  • Digital Object Identifier (doi)

    Author List

  • Wadhwa A; Kutny MA; Xavier AC
  • Volume

  • 65
  • Issue

  • 2